

IFWO

RAW SEQUENCE LISTING

DATE: 08/27/2004

PATENT APPLICATION: US/10/733,323

TIME: 14:30:12

Input Set : N:\Crf3\RULE60\10733323.raw Output Set: N:\CRF4\08272004\J733323.raw

```
1 <110> APPLICANT: ANTAKLY, Tony
                     SAIRAM, Ram M.
   3 <120> TITLE OF INVENTION: COMPOUNDS WITH ANTI-KS AND ANTI-HIV
                     ACTIVITY
  5 <130> FILE REFERENCE: 10662-71US FC/ntb
  6 <140> CURRENT APPLICATION NUMBER: US/10/733,323
                                                                                                                               7 <141> CURRENT FILING DATE: 2003-12-12
  8 <150> PRIOR APPLICATION NUMBER: US/09/494,500
  9 <151> PRIOR FILING DATE: 2000-01-31
                                                                                                                                      ENTERED
12 <150> PRIOR APPLICATION NUMBER: PCT/CA98/00731
13 <151> PRIOR FILING DATE: 1998-07-30
14 <150> PRIOR APPLICATION NUMBER: US 60/054,543
15 <151> PRIOR FILING DATE: 1997-08-01
                                                                                                                             AND PROPERTY OF THE PROPERTY O
16 <160> NUMBER OF SEQ ID NOS: 4
17 <170> SOFTWARE: FastSEQ for Windows Version 3.0
19 <210> SEQ ID NO: 1
20 <211> LENGTH: 20
21 <212> TYPE: PRT
22 <213> ORGANISM: Artificial Sequence
23 <220> FEATURE:
24 <223 > OTHER INFORMATION: anti-KS and anti-HIV compound
25 <400> SEQUENCE: 1
26
                       Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu
27
                       1
                                                                                                            10
28
                       Ala Val Glu Lys
29
31 <210> SEQ ID NO: 2
32 <211> LENGTH: 13
33 <212> TYPE: PRT
34 <213> ORGANISM: Artificial Sequence
35 <220> FEATURE:
36 <223> OTHER INFORMATION: anti-KS and anti-HIV compound
37 <400> SEQUENCE: 2
38
                       Ala Pro Asp Val Gln Asp Lys Phe Thr Arg Gln Ile Met
39
                         1
41 <210> SEQ ID NO: 3
42 <211> LENGTH: 15
43 <212> TYPE: PRT
44 <213> ORGANISM: Artificial Sequence
45 <220> FEATURE:
46 <223 > OTHER INFORMATION: anti-KS and anti-HIV compound
47 <223> OTHER INFORMATION: Xaa at positions 12, 14, and 15 are
                    unknown amino acid residues
```

RAW SEQUENCE LISTING

DATE: 08/27/2004

PATENT APPLICATION: US/10/733,323

TIME: 14:30:12

Input Set : N:\Crf3\RULE60\10733323.raw Output Set: N:\CRF4\08272004\J733323.raw

W>	49	<400>	3															
W>	50		Ala	Pro	Asp	Val	Gln	Asp	Lys	Phe	Thr	Arg	${\tt Gln}$	Xaa	Met	Xaa	Xaa	
	51		1				5					10					15	
	53	<210>	SEQ	ID N	0: 4													
	54	<211>	LENG	TH:	20													
	55	<212>	TYPE: PRT															
	56	<213>	ORGANISM: Artificial Sequence															
	57	<220>	FEATURE:															
	58	<223>	OTHER INFORMATION: anti-KS and anti-HIV compound															
	59	<223>	OTHER INFORMATION: Xaa at position 9 is an unknown															
	60		amino acid residue															
W>	61	<400>	4															
W>	62		Ser	Lys	Glu	Pro	Leu	Arg	Pro	Arg	Xaa	Arg	Pro	Ile	Asn	Ala	Thr L	ieu
	63		1				5					10					15	
	64		Ala	Val	Glu	Lys												
	65					20												

RAW SEQUENCE LISTING ERROR SUMMARY

PATENT APPLICATION: US/10/733,323

DATE: 08/27/2004 TIME: 14:30:13

Input Set : N:\Crf3\RULE60\10733323.raw
Output Set: N:\CRF4\08272004\J733323.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:3; Xaa Pos. 12,14,15

Seq#:4; Xaa Pos. 9

VARIABLE LOCATION SUMMARY

DATE: 08/27/2004

PATENT APPLICATION: US/10/733,323

TIME: 14:30:13

Input Set : N:\Crf3\RULE60\10733323.raw
Output Set: N:\CRF4\08272004\J733323.raw

Use of n's or Xaa's (NEW RULES):

Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present. in <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

Seq#:3; Xaa Pos. 12,14,15

Seq#:4; Xaa Pos. 9

VERIFICATION SUMMARY

L:62 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0

DATE: 08/27/2004

PATENT APPLICATION: US/10/733,323

TIME: 14:30:13

Input Set : N:\Crf3\RULE60\10733323.raw Output Set: N:\CRF4\08272004\J733323.raw

L:49 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:3 L:50 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:3 L:50 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:3 L:50 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0 L:61 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:4 L:62 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:4 L:62 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:4